Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614948 · ClinicalTrials.gov registry record · Phase 3
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 31,835
- Enrollment target
NCT04614948 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 31,835 participants.
The verdict
NCT04614948, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31,835 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.
Interventions
- OTHER Placebo
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31,835 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2023-06-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614948
The ClinicalTrials.gov registry entry for NCT04614948 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31,835 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04614948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614948 about?
NCT04614948 is a clinical study titled "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults". The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogen...
What is the current status of trial NCT04614948?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31,835 participants. The study started on 2020-11-12. Estimated completion is 2023-06-18.
What interventions are being tested in trial NCT04614948?
The interventions under investigation include: Placebo (OTHER), Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614948?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.